PF-Atlas › Clinical Trials › NCT02477709
A Study to Assess the Tolerability of a Single Dose of Gefapixant in Subjects With Idiopathic Pulmonary Fibrosis
Gefapixant · Phase 2
Registry ID
NCT02477709
Phase
Phase 2
Status
Completed
Drug / intervention
Gefapixant
Sponsor
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Start
2015-07-20
Enrollment
6
Locations
1
About this trial
This study assesses the tolerability of a single dose of gefapixant (AF-219) in participants with idiopathic pulmonary fibrosis (IPF). Six eligible participants will receive a single 150 mg dose of gefapixant and undergo tolerability and PK assessments.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT02477709 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.